Review of current treatment in panic disorder

JA den Boer*, BR Slaap

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

29 Citations (Scopus)

Abstract

The ideal properties for an antipanic agent include the ability to provide complete recovery from panic attacks, resolution of associated anxiety and avoidance behavior, relapse prevention, good tolerability, and efficacy in comorbid conditions including depression. We compared the properties of currently available treatment options for panic attacks, including the benzodiazepines, tricyclic antidepressants, monoamine oxidase inhibitors and selective serotonin reuptake inhibitors (SSRIs), with this ideal. Experimental approaches in the development of therapeutic agents of potential use against panic disorder were also examined. It is clear that SSRIs, such as paroxetine, are an effective treatment for panic disorder, and their antidepressant activity also allows concurrent treatment of comorbid depressive disorders, for which patients with panic disorder are at high risk. However, despite the availability of effective antipanic agents, some patients do not respond to treatment. (C) 1998 Lippincott-Raven Publishers.

Original languageEnglish
Pages (from-to)S25-S30
Number of pages6
JournalINTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
Volume13
Publication statusPublished - Apr-1998
Event10th Annual Congress of the European-College-of-Neuropsychopharmacology - , Austria
Duration: 13-Sep-199717-Sep-1997

Keywords

  • anxiety
  • benzodiazepines
  • panic attacks
  • panic disorder
  • selective serotonin reuptake inhibitors
  • tricyclic antidepressants
  • PLACEBO-CONTROLLED TRIAL
  • DOUBLE-BLIND
  • CHOLECYSTOKININ-TETRAPEPTIDE
  • ENHANCED SENSITIVITY
  • RECEPTOR ANTAGONIST
  • ANXIETY DISORDERS
  • UPTAKE INHIBITOR
  • DRUG-THERAPY
  • FOLLOW-UP
  • FLUVOXAMINE

Cite this